Ginkgo Bioworks Holdings, Inc.
DNA
$6.79
-$0.45-6.22%
NYSE
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 20.16M | 19.47M | 33.40M | 38.84M | 39.13M |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 20.16M | 19.47M | 33.40M | 38.84M | 39.13M |
| Cost of Revenue | 1.72M | 3.10M | 7.30M | 12.80M | 5.38M |
| Gross Profit | 18.44M | 16.38M | 26.10M | 26.04M | 33.75M |
| SG&A Expenses | 29.67M | 37.83M | 46.01M | 44.95M | 38.60M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 77.60M | 90.85M | 103.44M | 127.11M | 97.35M |
| Operating Income | -57.44M | -71.37M | -70.05M | -88.27M | -58.21M |
| Income Before Tax | -57.19M | -76.14M | -81.39M | -80.75M | -53.48M |
| Income Tax Expenses | 128.00K | -80.00K | -643.00K | 1.00K | -283.00K |
| Earnings from Continuing Operations | -57.32M | -76.06M | -80.75M | -80.76M | -53.19M |
| Earnings from Discontinued Operations | 10.61M | -6.53M | -- | -- | -7.11M |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -46.71M | -82.59M | -80.75M | -80.76M | -60.30M |
| EBIT | -57.44M | -71.37M | -70.05M | -88.27M | -58.21M |
| EBITDA | -40.93M | -62.78M | -61.08M | -88.10M | -38.77M |
| EPS Basic | -0.75 | -1.39 | -1.41 | -1.45 | -1.10 |
| Normalized Basic EPS | -0.58 | -0.72 | -0.68 | -0.93 | -0.61 |
| EPS Diluted | -0.75 | -1.39 | -1.42 | -1.45 | -1.10 |
| Normalized Diluted EPS | -0.58 | -0.72 | -0.68 | -0.93 | -0.61 |
| Average Basic Shares Outstanding | 62.09M | 59.56M | 57.08M | 55.63M | 54.86M |
| Average Diluted Shares Outstanding | 62.09M | 59.56M | 57.08M | 55.63M | 54.86M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |